Phase 1 Pulmonary Hypertension Trial, Recruiting NCT04624490 Sponsor: Mario Castro, MD, MPH Condition: Pulmonary Hypertension
Back to Pulmonary Hypertension

Phase 1 Pulmonary Hypertension Trial, Recruiting

NCT04624490
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

If you are a healthy volunteer:

  • You have no diagnosed lung conditions
  • You are able to read and understand English or Spanish

If you have a lung condition:

  • A doctor has diagnosed you with a lung or breathing problem
  • Your lung condition has not gotten worse in the past 30 days
  • You are able to read and understand English or Spanish

Who may not be able to join:

  • You have a reason why having an MRI scan would not be safe for you (such as certain metal implants — confirm with trial site)
  • You are currently pregnant or breastfeeding
  • The special vest worn during the MRI scan does not fit your body size
  • You are unable to hold your breath for 15 to 16 seconds
  • You may have difficulty following instructions during the scan
  • The level of oxygen in your blood is too low, even when using extra oxygen support
  • You have a cognitive or memory condition that would prevent you from giving informed consent to take part
  • You are currently living in an institution (such as a care facility) (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 21 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Peter Niedbalski, PHD, University of Kansas Medical Center

Phone: 913-945-9399

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Sponsor
Mario Castro, MD, MPH
Registry
ClinicalTrials.gov
Start date
2 November 2020
Est. completion
26 October 2028

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

RBC/Barrier Ratio

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov